ReviewVaccines2015
Gavi HPV Programs: Application to Implementation.
Review in Vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Distribution of high- and low-risk human papillomavirus genotypes and their prophylactic vaccination coverage among West African women: systematic review.Journal of the Egyptian National Cancer Institute · 2023Pooled it
- Barriers and facilitators to implementation of cancer treatment and palliative care strategies in low- and middle-income countries: systematic review.International journal of public health · 2018Pooled it
- Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.PharmacoEconomics · 2017Pooled it
- Preventive insights and practices of female health professionals regarding cervical cell dysplasia: a cross-sectional study in Egypt.BMC public health · 2025Article
- Understanding HPV Vaccination Policymaking in Rwanda: A Case of Health Prioritization and Public-Private-Partnership in a Low-Resource Setting.International journal of environmental research and public health · 2023Article
- Nurses and doctors 's awareness and knowledge towards treatment and care of cervical cancer patients: a cross-sectional study.BMC nursing · 2023Article
- Spotlight on Human Papillomavirus Vaccination Coverage: Is Nigeria Making Any Progress?JCO global oncology · 2023Article
- Article
- Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment.Human vaccines & immunotherapeutics · 2022Article
- Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction.Vaccine · 2022Article
- Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.Vaccine · 2022Article
- Article
- National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.Vaccine · 2022Review
- Article
- Feasibility and acceptability of nationwide HPV vaccine introduction in Senegal: Findings from community-level cross-sectional surveys, 2020.PLOS global public health · 2022Article
- Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery.PLOS global public health · 2022Article
- Review
- National action towards a world free of cervical cancer for all women.Preventive medicine · 2021Article
- A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.Frontiers in public health · 2021Article
- Delay in Diagnosis of Cervical Cancer in Afghanistan: A Pilot Cross-Sectional Survey.Frontiers in reproductive health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.